A detailed history of Lindbrook Capital, LLC transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 6 shares of DCTH stock, worth $93. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6
Previous 6 -0.0%
Holding current value
$93
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$3.62 - $6.55 $18 - $32
-5 Reduced 45.45%
6 $0
Q1 2022

Apr 21, 2022

BUY
$5.64 - $7.95 $11 - $15
2 Added 22.22%
11 $0
Q2 2021

Jul 27, 2021

BUY
$9.54 - $15.1 $85 - $135
9 New
9 $0

Others Institutions Holding DCTH

About DELCATH SYSTEMS, INC.


  • Ticker DCTH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 8,597,680
  • Market Cap $134M
  • Description
  • Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...
More about DCTH
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.